Exhibit 99.3

1 Platinum refractory or resistant serous ovarian carcinoma. 2 NSCLC = Non-small cell lung cancer 3 Program is wholly owned, development costs being provided by the Bill & Melinda Gates Foundation (BMGF), Immunocore retains all development and commercialization rights in the developed world. 4 Program is not HLA restricted (i.e. universal for all populations). 5 Submission Leading bispecific TCR pipeline Candidate Target (HLA type) Indication IND-enabling Phase 1 Phase 2 Phase 3 Approved gp100-A02 Uveal (ocular) melanoma On Market Adjuvant uveal (ocular) melanoma Phase 3 ongoing 2L+ advanced cutaneous melanoma Phase 3 enrolment completion | 1H26 Brenetafusp PRAME-A02 1L advanced cutaneous melanoma Phase 3 ongoing Combo arms Ovarian1 Phase 1/2 ongoing NSCLC2 Additional solid tumors IMC-P115C PRAME HLE-A02 Multiple solid tumors Phase 1/2 ongoing IMC-T119C PRAME-A24 Multiple solid tumors IMC-R117C PIWIL1-A02 Colorectal and GI cancers Phase 1/2 ongoing IMC-M113V3 Gag-A02 Human Immunodeficiency Virus (HIV) MAD Data | 1Q 2025 IMC-I109V Envelope-A02 Hepatitis B Virus (HBV) SAD Data | 2025 IMC-S118AI PPI x PD1-A02 Type 1 Diabetes CTA/IND5 | 4Q 2025 IMC-U120AI CD1a x PD1 (non-HLA restricted) Dermatology CTA/IND5 | 2026 Oncology Infectious Autoimmune TEBE-AM PRISM-MEL-301 ATOM sponsored by